• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series.乌帕替尼在16例托法替布难治性溃疡性结肠炎患者中的应用：一项单中心病例系列研究
Inflamm Bowel Dis. 2024 Nov 4;30(11):2232-2235. doi: 10.1093/ibd/izad279.
2
Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan.乌帕替尼与托法替布治疗溃疡性结肠炎的短期疗效比较：日本一项为期24周的真实世界研究
Intest Res. 2025 Mar 20. doi: 10.5217/ir.2024.00187.
3
Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series.在皮质类固醇和英夫利昔单抗难治性急性重症溃疡性结肠炎中使用JAK抑制剂的序贯挽救疗法：病例系列
Therap Adv Gastroenterol. 2025 Mar 30;18:17562848251323511. doi: 10.1177/17562848251323511. eCollection 2025.
4
One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study.乌帕替尼与托法替布治疗溃疡性结肠炎的一年比较疗效：一项多中心队列研究
Am J Gastroenterol. 2024 Apr 1. doi: 10.14309/ajg.0000000000002746.
5
Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis.乌帕替尼 salvage 治疗英夫利昔单抗治疗经验的急性重度溃疡性结肠炎患者。
J Crohns Colitis. 2023 Dec 30;17(12):2033-2036. doi: 10.1093/ecco-jcc/jjad115.
6
Upadacitinib Monotherapy After Tofacitinib Failure Was Successful for Induction But Not Maintenance of Remission in Medically Refractory Ulcerative Colitis.托法替布治疗失败后，乌帕替尼单药疗法对难治性溃疡性结肠炎的诱导缓解有效，但维持缓解无效。
ACG Case Rep J. 2025 Apr 16;12(4):e01673. doi: 10.14309/crj.0000000000001673. eCollection 2025 Apr.
7
Upadacitinib Results in Endoscopic Remission in Patients With Inflammatory Bowel Disease and Prior Tofacitinib Failure.乌帕替尼可使炎症性肠病且先前托法替布治疗失败的患者实现内镜缓解。
J Clin Gastroenterol. 2025 Mar 6. doi: 10.1097/MCG.0000000000002157.
8
Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study.乌帕替尼诱导治疗对溃疡性结肠炎患者有效且安全，包括那些既往使用过托法替布的患者：一项多中心真实世界队列研究。
Intest Res. 2024 Dec 20. doi: 10.5217/ir.2024.00127.
9
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
10
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in Japan.三种 Janus 激酶抑制剂治疗溃疡性结肠炎的疗效和安全性比较：日本一项真实世界多中心研究
Aliment Pharmacol Ther. 2025 Feb;61(3):524-537. doi: 10.1111/apt.18406. Epub 2024 Nov 22.

引用本文的文献

1
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.第二种JAK抑制剂治疗溃疡性结肠炎的有效性和安全性：J2J多中心研究
Aliment Pharmacol Ther. 2025 Aug;62(4):430-439. doi: 10.1111/apt.70199. Epub 2025 May 22.
2
Upadacitinib Monotherapy After Tofacitinib Failure Was Successful for Induction But Not Maintenance of Remission in Medically Refractory Ulcerative Colitis.托法替布治疗失败后，乌帕替尼单药疗法对难治性溃疡性结肠炎的诱导缓解有效，但维持缓解无效。
ACG Case Rep J. 2025 Apr 16;12(4):e01673. doi: 10.14309/crj.0000000000001673. eCollection 2025 Apr.
3
Real-World Effectiveness and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis.乌帕替尼治疗溃疡性结肠炎患者的真实世界有效性和安全性：一项系统评价和荟萃分析
J Clin Med. 2025 Mar 25;14(7):2232. doi: 10.3390/jcm14072232.
4
Upadacitinib Results in Endoscopic Remission in Patients With Inflammatory Bowel Disease and Prior Tofacitinib Failure.乌帕替尼可使炎症性肠病且先前托法替布治疗失败的患者实现内镜缓解。
J Clin Gastroenterol. 2025 Mar 6. doi: 10.1097/MCG.0000000000002157.
5
Live from Fuzhuan Brick Tea Alleviates DSS-Induced Colitis by Intestinal Barrier Restoration and Suppressing NLRP3 Signaling Pathway Regulation.茯砖茶提取物通过恢复肠道屏障和抑制NLRP3信号通路调控减轻葡聚糖硫酸钠诱导的结肠炎。
Foods. 2025 Feb 7;14(4):549. doi: 10.3390/foods14040549.
6
Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis.Janus激酶抑制剂在溃疡性结肠炎中的疗效与安全性
J Clin Med. 2024 Nov 27;13(23):7186. doi: 10.3390/jcm13237186.
7
Safety and Effectiveness of Thiopurines and Small Molecules in Elderly Patients with Inflammatory Bowel Diseases.硫嘌呤类药物和小分子药物在老年炎症性肠病患者中的安全性和有效性
J Clin Med. 2024 Aug 9;13(16):4678. doi: 10.3390/jcm13164678.
8
Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?所有用于治疗炎症性肠病的Janus激酶抑制剂都一样吗？
Gastroenterol Hepatol (N Y). 2023 Dec;19(12):727-738.

本文引用的文献

1
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.乌帕替尼在溃疡性结肠炎和克罗恩病中均有效且安全：前瞻性真实世界经验。
Clin Gastroenterol Hepatol. 2023 Jul;21(7):1913-1923.e2. doi: 10.1016/j.cgh.2023.03.001. Epub 2023 Mar 8.
2
Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.双重靶向治疗部分或无应答炎症性肠病的疗效和安全性：文献系统评价。
Dig Dis Sci. 2023 Jun;68(6):2604-2623. doi: 10.1007/s10620-023-07837-0. Epub 2023 Feb 20.
3
Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond.文章主题：2022年及以后溃疡性结肠炎治疗方法的定位
Curr Gastroenterol Rep. 2022 Dec;24(12):157-170. doi: 10.1007/s11894-022-00853-6. Epub 2022 Nov 3.
4
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
5
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.生物疗法和小分子药物治疗中重度溃疡性结肠炎的疗效：系统评价与网状Meta分析
Gut. 2021 Dec 22. doi: 10.1136/gutjnl-2021-326390.
6
Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?炎症性肠病中抗TNF药物的原发性失效：更换（为第二种抗TNF药物）还是替换（为另一种作用机制的药物）？
J Clin Med. 2021 Nov 15;10(22):5318. doi: 10.3390/jcm10225318.
7
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.欧洲克罗恩病和结肠炎组织（ECCO）溃疡性结肠炎治疗指南：药物治疗
J Crohns Colitis. 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178.
8
ACG Clinical Guideline: Ulcerative Colitis in Adults.ACG 临床指南：成人溃疡性结肠炎。
Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152.

Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series.

作者信息

Levine Jake, McKibbin Jey, Ham Rebecca, Cohen-Mekelburg Shirley, Bishu Shrinivas, Tang Kevin, Higgins Peter D R, Berinstein Jeffrey A

机构信息

Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.

Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI, USA.

出版信息

Inflamm Bowel Dis. 2024 Nov 4;30(11):2232-2235. doi: 10.1093/ibd/izad279.

DOI:10.1093/ibd/izad279
PMID:38142124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12102464/
Abstract
摘要